Establishment and Characterization of DLBCL Cell Lines

RL (GCB-DLBCL) and U2932 (ABC-DLBCL) cell lines were obtained from American Type Culture Collection (Rockville, MD). Rituximab-resistant cell lines (RL 4RH and U2932 4RH) were created as described previously (Czuczman et al. 2008 (link)). Other cell lines representing ABC-DLBCL (TMD8, HBL-1) and GCB-DLBCL (SUDHL-4, SUDHL-6, SUDHL-10, OCI-LY2, OCI-LY19, BJAB, HT, DB, Karpas-422, NUDHL-1) were obtained from Leibniz Institute/German Collection of Microorganisms and Cell Cultures (DSMZ). All cell lines were maintained in RPMI 1640 (Life Technologies, Grand Island, NY) supplemented with 10% heat-inactivated fetal bovine serum (Atlanta Biologicals, Norcross, GA), 5mM HEPES, 100U/mL penicillin and 100μg/mL streptomycin (Life Technologies, Grand Island, NY) at 37^oC and 5%CO₂.
Neoplastic B-cells were isolated from pre-treatment biopsy tissue (either lymph node or extranodal tumor tissue) obtained from patients with B-cell NHL or Hodgkin lymphoma (HL) receiving therapy at Roswell Park Comprehensive Cancer Center (RPCCC) as previously described (Brem et al. 2011 (link)).

Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link: Access Free Full Text.

Torka P., Mavis C., Kothari S., Belliotti S., Gu J., Sundaram S., Barth M, & Hernandez‐Ilizaliturri F.J. (2020). Pevonedistat, a NEDD8‐activating enzyme inhibitor, induces apoptosis and augments efficacy of chemotherapy and small molecule inhibitors in pre‐clinical models of diffuse large B‐cell lymphoma. EJHaem, 1(1), 122-132.

Publication 2020

RL (GCB-DLBCL) U2932 (ABC-DLBCL) SUDHL-4 SUDHL-6 OCI-LY19 Karpas-422 NUDHL-1 RPMI 1640 fetal bovine serum HEPES penicillin streptomycin

B cell Biologicals Biopsy Cancer Cell cultures Cell lines Fetal bovine serum Hepes Hodgkin lymphoma Lymph node Patients Penicillin Rituximab Streptomycin Therapy Tissue Tumor

Corresponding Organization : Roswell Park Comprehensive Cancer Center

Other organizations : Yale University

Top 5 similar protocols

Variable analysis

independent variables

Cell lines: RL (GCB-DLBCL), U2932 (ABC-DLBCL), RL 4RH (rituximab-resistant RL), U2932 4RH (rituximab-resistant U2932), TMD8 (ABC-DLBCL), HBL-1 (ABC-DLBCL), SUDHL-4 (GCB-DLBCL), SUDHL-6 (GCB-DLBCL), SUDHL-10 (GCB-DLBCL), OCI-LY2 (GCB-DLBCL), OCI-LY19 (GCB-DLBCL), BJAB (GCB-DLBCL), HT (GCB-DLBCL), DB (GCB-DLBCL), Karpas-422 (GCB-DLBCL), NUDHL-1 (GCB-DLBCL)

dependent variables

Not explicitly mentioned

control variables

Cell culture medium: RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum, 5mM HEPES, 100U/mL penicillin and 100μg/mL streptomycin
Cell culture conditions: 37°C and 5% CO2

controls

Positive control: Not specified
Negative control: Not specified

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!